Key highlights

  • AVH touched a 52-week high on 21 October 2026 and closed at $3.99, up 5.56% for the day.
  • An 18 August 2026 release reported that the PermeaDerm-I study met its primary endpoint, showing a 70% cost advantage over allograft.
  • Clinical outcomes were comparable to allograft, with a 95.7% reduction in preparation time.

During the Trading session on 21 October 2026, Avita Medical Inc (ASX:AVH) shares reached a 52-week high. The stock’s closing price was $3.99, up 5.56% on the day. AVITA Medical is a therapeutic acute wound care company dual-listed on Nasdaq and the ASX.

What AVITA Medical does

AVITA Medical, Inc. develops and sells products for wound care and skin restoration, including the RECELL system and PermeaDerm, a biosynthetic wound matrix. It is listed on NASDAQ as RCEL and on the ASX as AVH.

PermeaDerm-I study results

In a release dated 18 August 2026, AVITA announced positive results from its multicentre randomised PermeaDerm-I study. PermeaDerm delivered clinically comparable outcomes to cadaveric allograft while reducing product cost by 70%: mean treatment cost was US$148.70 per 1% of total body surface area treated, against US$497.10 for allograft, a saving of about US$348 (p<0.001).

Preparation time fell 95.7%, as the off-the-shelf product removes tissue tracking, thawing and meshing. About 94% of PermeaDerm patients achieved at least 95% graft take one week after autografting, comparable to allograft, all patients in both groups reached 95% or greater wound healing by eight weeks, and no adverse events were attributed to PermeaDerm.

Sector context

Healthcare and medical technology companies are assessed on clinical progress, regulatory approvals and commercial uptake, and share prices can be volatile around such events.

Risks and uncertainties

The study results are one clinical dataset, and commercial adoption depends on hospital purchasing, reimbursement and competition from allograft and other products. Closing prices on a single day are not the same as the 52-week high or low price, and a 52-week extreme does not indicate where a share price will move next.

Catalysts to watch

Items to watch include commercial uptake of PermeaDerm, further study publication and the company’s next quarterly results.

Closing perspective

AVITA’s 18 August 2026 release reported PermeaDerm met its primary endpoint on cost. Later updates will show commercial progress.